Skip to main content
All products sold for laboratory research purposes only. Not for human or veterinary use.
Unconditional free shipping — every order, nationwide
Bench Grade Peptides

GLP-1 S

Single-receptor incretin class agonist studied in incretin-pathway metabolic research.

GLP-1 S is Bench Grade's catalog designation for a long-acting synthetic analog in the GLP-1 receptor agonist class. Native GLP-1 — glucagon-like peptide-1 — is an incretin hormone released by intestinal L-cells after a meal; it potentiates glucose-dependent insulin secretion, slows gastric emptying, and signals satiety through receptors in the hypothalamus.

The analog class this compound belongs to modifies the native sequence for protease resistance and albumin binding, extending a half-life measured in minutes into one measured in days. That pharmacokinetic difference is what made the class the most studied peptide family of the last decade, and it is why receptor-signaling, metabolic-pathway, and appetite-circuit laboratories keep standard reference material on hand.

Bench Grade supplies GLP-1 S as lyophilized powder with per-lot HPLC verification. It is research material for receptor and metabolic studies — not a pharmaceutical product, and not a substitute for one.

Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it is not approved by the FDA for human or veterinary use, and nothing here is a protocol or a recommendation.

Published research

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity
    Wilding JPH, et al. N Engl J Med. 2021.PubMed →
  • Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)
    Davies M, et al. Lancet. 2021.PubMed →
  • Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)
    Wadden TA, et al. JAMA. 2021.PubMed →
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
    Frías JP, et al. N Engl J Med. 2021.PubMed →
  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso SP, et al. N Engl J Med. 2016.PubMed →
  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso SP, et al. N Engl J Med. 2016.PubMed →
  • A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
    Pi-Sunyer X, et al. N Engl J Med. 2015.PubMed →
  • Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus
    Scuderi MA, et al. Domest Anim Endocrinol. 2018.Animal modelPubMed →

Further reading in the lab library

Researchers also ordered

Browse the catalog